|
|
| Line 27: |
Line 27: |
|
| |
|
| [[Human respiratory syncytial virus medical therapy|Medical Therapy]] | [[Human respiratory syncytial virus primary prevention|Prevention]] | [[Human respiratory syncytial virus cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Human respiratory syncytial virus future or investigational therapies|Future or Investigational Therapies]] | | [[Human respiratory syncytial virus medical therapy|Medical Therapy]] | [[Human respiratory syncytial virus primary prevention|Prevention]] | [[Human respiratory syncytial virus cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Human respiratory syncytial virus future or investigational therapies|Future or Investigational Therapies]] |
|
| |
| * Respiratory syncytial virus treatment
| |
| :* Supportive therapy
| |
| ::* Hydration and supplemental oxygen.
| |
| ::* Routine use of [[Ribavirin]] not recommended. [[Ribavirin]] therapy associated with small increases in O2 saturation.
| |
| ::* No consistent decrease in need for mechanical ventilation or ICU stays. High cost, aerosol administration and potential toxicity<ref name="pmid19736258">{{cite journal| author=Committee on Infectious Diseases| title=From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. | journal=Pediatrics | year= 2009 | volume= 124 | issue= 6 | pages= 1694-701 | pmid=19736258 | doi=10.1542/peds.2009-2345 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19736258 }} </ref>
| |
| ::* Note (1) In adults, Respiratory syncytial virus accounted for 10.6% of hospitalizations for pneumonia, 11.4% for COPD, 7.2% for asthma & 5.4% for CHF in pts >65 yrs of age <ref name="pmid15858184">{{cite journal| author=Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE| title=Respiratory syncytial virus infection in elderly and high-risk adults. | journal=N Engl J Med | year= 2005 | volume= 352 | issue= 17 | pages= 1749-59 | pmid=15858184 | doi=10.1056/NEJMoa043951 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15858184 }} </ref>. Respiratory syncytial virus caused 11% of clinically important respiratory illnesses in military recruits<ref name="pmid16007526">{{cite journal| author=O'Shea MK, Ryan MA, Hawksworth AW, Alsip BJ, Gray GC| title=Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. | journal=Clin Infect Dis | year= 2005 | volume= 41 | issue= 3 | pages= 311-7 | pmid=16007526 | doi=10.1086/431591 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16007526 }} </ref>
| |
| ::* Note (2) Respiratory Syncytial Virus major cause of morbidity in neonates/infants.
| |
| ::* Note (3) Nucleic acid test now approved to detect 12 respiratory viruses (xTAG Respiratory Viral Panel, Luminex Molecular Diagnostics).
| |
| :* '''Prevention of Respiratory syncytial virus'''
| |
| ::* 1. In children <24 months old with chronic lung disease of prematurity (formerly broncho-pulmonary dysplasia) requiring supplemental oxygen or
| |
| ::* 2. In premature infants (<32 wks gestation) and <6 months old at start of Respiratory syncytial virus season or
| |
| ::* 3. In children with selected congenital heart diseases.
| |
| :::* Preferred regimen for prevention of Respiratory syncytial virus: [[Palivizumab]] (Synagis) 15 mg per kg IM q month Nov.-April<ref name="pmid19736258">{{cite journal| author=Committee on Infectious Diseases| title=From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. | journal=Pediatrics | year= 2009 | volume= 124 | issue= 6 | pages= 1694-701 | pmid=19736258 | doi=10.1542/peds.2009-2345 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19736258 }} </ref>
| |
| :::* Note : Significant reduction in Respiratory syncytial virus hospitalization among children with congenital heart disease<ref name="pmid17727335">{{cite journal| author=Feltes TF, Sondheimer HM| title=Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease. | journal=Expert Opin Biol Ther | year= 2007 | volume= 7 | issue= 9 | pages= 1471-80 | pmid=17727335 | doi=10.1517/14712598.7.9.1471 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17727335 }} </ref>
| |
|
| |
|
| ==Case Studies== | | ==Case Studies== |